Yinuoke Publication Describes a New, Orally Delivered Molecule That Reverses Cancer Cachexia and Increases Survival Using in Vivo Models

On February 13, 2024, Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients, announced publication of a manuscript in the Journal of Cachexia, Sarcopenia and Muscle demonstrating the effectiveness of a new compound in alleviating cachexia and increasing the survival of tumor-bearing mice in a T-cell dependent manner. Cancer cachexia, a devastating tumor-induced immune disorder leading to body wasting and reduced tolerability to therapeutics, occurs in 80% of all cancer patients and causes 25% of deaths. Previous attempts to treat cachexia have failed due to lack of efficacy in stabilizing patient weight and strength. Yinuoke treats cachexia as a tumor-driven autoimmune disorder rather than a metabolic condition. The new drug, YNK105 (R-ketorolac), is an R-enantiomer of an existing racemic NSAID (ketorolac) which cannot be used for a long term due to toxicity). YNK105 reduces systemic inflammation without the toxic side effects caused by existing NSAIDs that limit their use.

Login Or Register To Read Full Story